Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 6

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 6
---
 other than statements of historical fact, contained herein, including statements regarding our plans, objectives and expectations for our business, operations and financial performance and condition, and can be identified by terminology such as “anticipate,” “believe,” “contemplate,” “continue” “could,” “estimate,” “estimate,” “expect,” “goal,” “hope,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” “can,” “future” or the negative of these words or other similar expressions. Forward-looking statements are based on management’s belief and assumptions and on information currently available to management. Although we believe that the expectations reflected in forward-looking statements are reasonable, such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements.

These forward-looking statements include, but are not limited to, statements about:

• the initiation, timing, progress and results of our research and development programs, product candidates, preclinical studies and future clinical trials;

• our ability to demonstrate, and the timing of, preclinical proof-of-concept in vivo for multiple programs;

• our ability to advance any current and future product candidates that we may identify and successfully complete any clinical studies, including the manufacture of any such product candidates;

• our ability to pursue our areas of focus and any other additional programs we may advance;

• our ability to quickly leverage programs within our initial target indications and to progress additional programs to further develop our pipeline;

• the timing of our investigational new drug (“IND”) application submissions;

• the ability of our Prime Editing technology to address unmet medical needs in patients;

• the implementation of our strategic plans for our business, programs and technology;

• the scope and duration of protection we are able to establish and maintain for intellectual property rights covering our Prime Editing technology;

• developments related to our competitors and our industry;

• our ability to leverage the clinical, regulatory, and manufacturing advancements made by gene therapy and gene editing programs to accelerate our clinical trials and approval of product candidates;

• our ability to maintain existing collaborations or strategic relationships, to identify and enter into future license agreements and collaborations on favorable terms, if at all, and to realize the